Dorzolamide / Timolol: 4 agencies, 2006–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused dorzolamide / timolol: all 8 decisive outcomes across 3 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 18.2 years separate the first record, 11 Dec 2006 at SMC (Scotland), from the most recent, 12 Feb 2025 at HAS (France).
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for dorzolamide / timolol by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 10 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess dorzolamide / timolol, on 11 Dec 2006; PBAC (Australia) did not open a file until 2022 — an unusually long tail of 15.6 years between the earliest and latest system to look at it.
2 of the 4 agencies here assessed dorzolamide / timolol more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed dorzolamide / timolol.
The full ledger for dorzolamide / timolol reads 7 recommended, 2 not assessed and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 12 Feb 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2022 | Elevated intra-ocular pressure | Recommended | source |
| HAS (France) | 4 Nov 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 26 Jul 2018 | Treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when… | outside AWMSG criteria | source |
| SMC (Scotland) | 11 Dec 2006 | Elevated intra-ocular pressure in patients with open-angle glaucoma and pseudo-exfoliative glaucoma | accepted (restricted) | source |
5 further decisions for dorzolamide / timolol, across 2 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- latanoprost — same ATC class S01E — Ophthalmologicals
- bimatoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- latanoprost / timolol — same ATC class S01E — Ophthalmologicals
- bimatoprost / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / netarsudil — same ATC class S01E — Ophthalmologicals
Coverage: 10 decisions for dorzolamide / timolol from 4 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.